Leslie M. Shaw, Ph.D.

faculty photo
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Director, Alzheimer's Disease Neuroimaging, Initiative Biomarker Core Laboratory, University of Pennsylvania
Department: Pathology and Laboratory Medicine

Contact information
Hospital of the University of Pennsylvania
7.103 Founders Pavilion 3400 Spruce Street
Philadelphia, PA 19104
Office: (215) 662-6575
Fax: (215) 662-7529
B.S. (Cum Laude, Chemistry)
LeMoyne College, Syracuse, New York, 1962.
Ph.D. (Biochemistry)
S.U.N.Y. at Upstate Medical Center, 1968.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Development, validation and implementation of neurodegenerative diseases biomarkers in cerebrospinal fluid and plasma into treatment trials and clinical studies (eg, ADNI study; UPENN ADRC; PPMI study). These studies include the use of manual and highly automated immunoassays and for amyloid beta(1-42), U-p53AZ and for total tau the use of high sensitivity UPLC/tandem mass spectrometry. Multi-modal statistical analyses of these study data to address several questions including the diagnostic utilities of these biomarkers; assessments of the longitudinal trajectories of these biomarkers in AD, MCI and cognitively normal controls to assess the neuropathological changes over time in these individuals.

Description of Clinical Expertise

Measurement and interpretation of the toxicokinetics of drugs and toxins in patients affected by them. Interpretation of the pharmacokinetics of immunosuppressant maintenance medications in transplant patients.

Description of Other Expertise

Development and implementation of mass spectrometry-based methods for measuring small molecules of clinical utility including therapeutic drugs, toxins and special chemistry tests including Xylazine; 25-OH vitamin D; and biologicals, eg, Infliximab.

Selected Publications

Zicha S, Bateman RJ, Shaw LM, Zetterberg H, Bannon AW, Horton WA, et al.: Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity. Alz Dementia 2022 Notes: DOI: 10.1002/alz.12697.

Dalaby C, Teunissen CE, Blennow K, Alcolea D, Arisi I, Amar EB, …Shaw LM,…Lehman S. : Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer’s disease: an international overview. Alzheimer’s and Dementia. 2022 Notes: DOI: 10.1002/alz.12545.

Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, Shaw LM, Masters CL, Fowler CJ, Trojanowski JQ, Korecka M, Martins RN, Janelidze S, Hansson O, Bateman RJ. : Validation of Plasma Amyloid-β42/40 for Detecting Alzheimer Disease Amyloid Plaques Neurology. 98: e688 - e699, 2022 Notes: DOI: 10.1212/WNL.0000000000013211.

Hampel H, Shaw LM, Aisen P, Chen C, Lleo A, Iwatsubo T, Iwata A, Yamada M, Ikeuchi T, Jia J, Wang H, Teunissen CE, Peskind E, Blennow K, Cummings J, Vergallo A.: State-of-the-Art of lumbar puncture and its place in the journey of patients with Alzheimer’s disease. Alzheimer’s and Dementia. 18: 159 - 177 2022.

Cousins KAQ, Shaw LM, Shellikeri S, Dratch L, Rosario L, Elman LB, et al.: Elevated plasma phosphorylated tau 181 in amyotrophic lateral sclerosis relates to lower motor neuron dysfunction. Ann Neurol 2022 2022 Notes: DOI: 10.1002/ana.26462.

Cousins KAQ, Phillips JS, Irwin DJ, Lee EB, Wolk DA, Shaw LM, Zetterberg H, Blennow K, Burke SE, Kinney NG, Gibbons GS, McMillan CT, Trojanowski JQ, Grossman M.: ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. Alzheimer's & Dementia. 17 (5): 822 - 30, 2021

Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suarez-Calvet M, Saha-Chaudhuri P, Lussier F, Kvartsberg H, Rial AM, Pascoal TA, Andreasson U, Scholl M, Weiner MW, Rosa-Neto P, Trojanowski JQ, Shaw LM, Blennow K, Zetterberg H, Alzheimer's Disease Neuroimaging Initiative.: Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Molecular Psychiatry. 26 (2) : 429 - 442, 2021

Libiger O, Shaw LM, Watson MH, Nairn AC, Umana KL, Biarnes MC, Canet-Aviles RM, Jack CR Jr, Breton YA, Cortes L, Chelsky D, Spellman DS, Baker SA, Raghavan N, Potter WZ, Alzheimer's Disease Neuroimaging Initiative (ADNI), Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, Longitudinal CSF Proteomics Project Team.: Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease. Alzheimer's & Dementia. 17 (12): 1976 - 87, 2021

Moon S, Kim S, Mankhong S, Choi SH, Vandijck M, Kostanjevecki V, Jeong JH, Yoon SJ, Park KW, Kim EJ, Yoon B, Kim HJ, Jang JW, Hong JY, Park DH, Shaw LM, Kang JH.: Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans. Alzheimer's Research & Therapy. 13 (1) : 22, 2021

Shaw LM, Iseli TA, Wiesenfeld D, Ramakrishnan A, Granger CL.: Postoperative pulmonary complications following major head and neck cancer surgery. International Journal of Oral & Maxillofacial Surgery. 50 (3) : 302 - 8, Mar 2021.

back to top
Last updated: 08/24/2022
The Trustees of the University of Pennsylvania